A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants
Latest Information Update: 23 Apr 2026
At a glance
- Drugs BW 20805 (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Argo Biopharma
Most Recent Events
- 21 Apr 2026 New trial record